Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 21: AXIOMATIC-TKR: Patients Treated with Milvexian Show Reduced Rate of Venous Thromboembolism
Author(s): Jeffrey Weitz Added: 2 years ago
Dr Jeffrey Weitz (Thrombosis & Atherosclerosis Research Institute, Ontario, CA) presents the results of the Axiomatic-TKR Study, a phase II dose-ranging study that aims to examine the effect of Milvexian versus Enoxaparin in the treatment of venous thromboembolism in patients undergoing total-knee replacement surgery.The study met its efficacy criteria, where the rate of thromboembolism was… View more

Vascular Disease and Surgery
Role of Newer Oral Anticoagulants for Post-operative Prophylaxis
Author(s): Han Naung Tun , May Thu Kyaw , Erik Rafflenbeul , et al Added: 1 year ago

Anticoagulation

Vascular Disease and Surgery
AHA 23: KABUKI: DOAC in Pts with CTEPH
Author(s): Kazuya Hosokawa , Abe Kotaro Added: 5 months ago
AHA 2023 — Dr Kazuya Hosokawa and Dr Abe Kotaro (Kyushu University Hospital, JP) join us to share the findings of the KABUKI trial (NCT04730037). The aim of KABUKI (Daiichi Sankyo) is to assess whether edoxaban, a direct factor Xa inhibitor, is noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary hypertension (CTEPH).This investigator-initiated, multicenter, phase 3… View more

Prevention & Chronic Conditions
Author(s): Julia Sikorska , James Uprichard Added: 3 years ago
For more than 50 years, oral vitamin K antagonists (VKAs) were the choice of anticoagulant for the long-term treatment and prevention of arterial and venous thromboembolic events (VTE). VKA treatment is safe and effective, if a high time in therapeutic range is achieved. However, achieving a stable, therapeutic international normalised ratio can prove challenging in the context of drug and food… View more

Anticoagulation

Prevention & Chronic Conditions
Job title: Professor of Angiology / Director University Clinic of Angiology
Prof Nils Kucher is aProfessor of Angiology and Director University Clinic of Angiology at University Hospital Zürich, Zürich, CH. He specialises in minimally invasive endovascular treatment of acute pulmonary embolism, acute deep vein thrombosis, and the post-thrombotic syndrome. From 2016-2017 he was Chief Physician of Angiology at University Hospital Bern, where earlier he fulfilled the… View more
Christian Ruff
Dr. Christian Thomas Ruff, MD, MPH serves as the Director of the Genetics Core Laboratory and holds the position of Assistant Professor of Medicine at Harvard Medical School, based at Brigham and Women’s Faulkner Hospital in Boston, Massachusetts.With a diverse educational background, Dr. Ruff graduated from Harvard University with a degree in Neurobiology before earning his medical degree at… View more
ACC 2021: The VOYAGER PAD Trial
Author(s): Rupert Bauersachs Added: 2 years ago
Prof Rupert Bauersachs (Clinic Darmstadt, Darmstadt, DE) discusses the results from the VOYAGER PAD trial.The aim of the trial was to evaluate rivaroxaban/aspirin compared with placebo/aspirin among patients with lower extremity peripheral artery disease (PAD) undergoing revascularization. Questions What is the VOYAGER PAD Trial and what does it aim to address? What was the study design,… View more

Vascular Disease and Surgery

Intervention
ESC 22: ACT: Anti-Coronavirus Therapies to Prevent Progression of COVID-19
Author(s): Sanjit Jolly Added: 1 year ago
ESC Congress 22 — Dr Sanjit Jolly (Population Health Research Institute, CA) talk about the Anti-Coronavirus Therapies (ACT) trials (NCT04324463). The data is from two parallel trials assessing the effects of interventions in inpatients and outpatients with COVID-19. The ACT trials are testing whether anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin in… View more

Anticoagulation

Vascular Disease and Surgery
Anticoagulant Therapy for Patients with Coronavirus Disease 2019: Urgent Need for Enhanced Awareness
Author(s): Maki Komiyama , Koji Hasegawa Added: 3 years ago
Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has generated a pandemic that has heavily affected the global population, with more than 5.2 million infected and more than 337,000 deaths worldwide recorded between the end of 2019 and 24 May 2020.1 In the absence of vaccines or specific targeted treatments, strategies to… View more

COVID-19
Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?
Author(s): Mahmoud Abdelnabi , Abdallah Almaghraby , Yehia Saleh Added: 3 years ago
Vitamin K antagonist (VKA) oral anticoagulants have been ruling the field of anticoagulation for cardiovascular indications for years now. Recently, this dominance has been threatened by the introduction of direct oral anticoagulants (DOACs), with abundant data highlighting their safety and efficacy. To date, recent guidelines have limited the use of DOACs to stroke prevention in patients with… View more

Anticoagulation